Results released April 1, 2026, by the American Society for Radiation Oncology (ASTRO), which represents more than 10,000 ...
An international group led by researchers from the RIKEN Center for Integrative Medical Sciences (IMS) in Japan has ...
Bone-only, osteoblastic disease and the absence of prior ARPI exposure define the optimal radium-223 candidate, while ...
The FDA has again rejected Replimune’s biologics license application for vusolimogene oderparepvec plus nivolumab for ...
Structural alterations in the genome, particularly those leading to fusion oncogenes, represent cornerstone events in the biology of both solid and ...